$MPLT insider trading
Over the last 12 months, MapLight Therapeutics insiders reported 7 buys totaling $174.9M and 31 sales totaling $25.8M across SEC Form 4 filings. 42% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $174.9M 7 events
- Sold · 12m
- $25.8M 31 events
- Events · 12m
- 38 Form 4 filings, grouped
- Insiders · 12m
- 13 distinct reporters
- 10b5-1 share
- 42% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Catalyst4, Inc.10% | ▲ Buy | 4,400,000 | $11.38 | $50.1M | +21% | indirect |
| Aug 3, 2026 | Lillie James WoodruffChief Scientific Officer · O | ▼ Sale | 22,082 | $12.54 | $277K | -9.8% | plan |
| Jul 30, 2026 | Catalyst4, Inc.10% | ▲ Buy | 1,209,225 | $12.66 | $15.3M | +6.1% | 4 tranches · indirect |
| Jul 28, 2026 | Cox TroyD | ▲ Buy | 15,620 | $9.52 | $149K | — | indirect |
| Jul 17, 2026 | Foff Erin PennockChief Medical Officer · O | ▼ Sale | 47,158 | $36.78 | $1.7M | -13.6% | plan · 9 tranches |
| Jul 17, 2026 | Hanson KristopherGeneral Counsel · O | ▼ Sale | 16,508 | $36.82 | $608K | -10.2% | 7 tranches |
| Jul 17, 2026 | GILLIS JONATHANCAO and Interim CFO · O | ▼ Sale | 36,979 | $37.12 | $1.4M | -20.4% | plan · 7 tranches |
| Jul 17, 2026 | Kreitzer AnatolChief Discovery Officer · O | ▼ Sale | 36,284 | $37.09 | $1.3M | -17.2% | plan · 7 tranches |
| Jul 17, 2026 | Kroeger Christopher A.Chief Executive Officer · O·D | ▼ Sale | 147,639 | $36.87 | $5.4M | -10.6% | 7 tranches |
| Jul 17, 2026 | Lillie James WoodruffChief Scientific Officer · O | ▼ Sale | 18,267 | $36.88 | $674K | -7.5% | 7 tranches |
| May 11, 2026 | Hanson KristopherGeneral Counsel · O | ▼ Sale | 13,917 | $30.13 | $419K | -7.9% | plan · 4 tranches |
| May 11, 2026 | Kroeger Christopher A.Chief Executive Officer · O·D | ▼ Sale | 68,491 | $28.47 | $1.9M | -4.3% | plan · 9 tranches |
| May 7, 2026 | Foff Erin PennockChief Medical Officer · O | ▼ Sale | 4,438 | $28.54 | $127K | -1.3% | plan · 2 tranches |
| May 7, 2026 | Lillie James WoodruffChief Scientific Officer · O | ▼ Sale | 721 | $28.28 | $20K | -0.3% | plan |
| May 6, 2026 | Setia VishwasChief Financial Officer · O | ▼ Sale | 36,371 | $28.17 | $1.0M | -9.3% | plan · 8 tranches |
| May 6, 2026 | Foff Erin PennockChief Medical Officer · O | ▼ Sale | 50,280 | $28.39 | $1.4M | -12.5% | plan · 8 tranches |
| May 6, 2026 | Lillie James WoodruffChief Scientific Officer · O | ▼ Sale | 51,707 | $28.4 | $1.5M | -17.5% | plan · 8 tranches |
| May 6, 2026 | Kroeger Christopher A.Chief Executive Officer · O·D | ▼ Sale | 49,744 | $28.39 | $1.4M | -3.1% | plan · 8 tranches |
| May 4, 2026 | Hanson KristopherGeneral Counsel · O | ▼ Sale | 13,917 | $27.89 | $388K | -7.3% | plan · 4 tranches |
| Apr 28, 2026 | GILLIS JONATHANCAAO and PAO · O | ▼ Sale | 69,835 | $29.89 | $2.1M | -27.8% | plan · 5 tranches |
| Apr 27, 2026 | Kreitzer AnatolChief Discovery Officer · O | ▼ Sale | 45,422 | $29.66 | $1.3M | -17.7% | plan · 3 tranches |
| Apr 16, 2026 | Setia VishwasChief Financial Officer · O | ▼ Sale | 2,922 | $26.89 | $79K | -0.7% | 3 tranches |
| Apr 16, 2026 | Foff Erin PennockChief Medical Officer · O | ▼ Sale | 3,213 | $27.03 | $87K | -0.8% | 3 tranches |
| Apr 16, 2026 | Hanson KristopherGeneral Counsel · O | ▼ Sale | 1,827 | $26.89 | $49K | -1% | 3 tranches |
| Apr 16, 2026 | Lillie James WoodruffChief Scientific Officer · O | ▼ Sale | 4,513 | $27.16 | $123K | -1.5% | 3 tranches |
| Apr 16, 2026 | Kroeger Christopher A.Chief Executive Officer · O·D | ▼ Sale | 19,187 | $27.16 | $521K | -1.2% | 3 tranches |
| Apr 15, 2026 | Kreitzer AnatolChief Discovery Officer · O | ▼ Sale | 3,316 | $26.61 | $88K | -1.3% | — |
| Apr 15, 2026 | Malenka Robert C.D | ▼ Sale | 8,593 | $26.9 | $231K | -2.6% | plan |
| Apr 15, 2026 | GILLIS JONATHANCAAO and PAO · O | ▼ Sale | 3,590 | $26.61 | $96K | -1.4% | — |
| Feb 24, 2026 | Malenka Robert C.D | ▼ Sale | 14,195 | $18.34 | $260K | -4.2% | 4 tranches |
| Feb 20, 2026 | Pavlov GeorgeD | ▲ Buy | 25,000 | $17.65 | $441K | — | 3 tranches |
| Feb 13, 2026 | Malenka Robert C.D | ▼ Sale | 12,116 | $18.21 | $221K | -3.4% | — |
| Feb 11, 2026 | Malenka Robert C.D | ▼ Sale | 6,863 | $18.12 | $124K | -1.9% | 2 tranches |
| Feb 10, 2026 | Garnett Timothy JohnD | ▲ Buy | 14,124 | $17.89 | $253K | — | indirect |
| Feb 3, 2026 | Malenka Robert C.D | ▼ Sale | 7,040 | $18.02 | $127K | -1.9% | 2 tranches |
| Jan 30, 2026 | Malenka Robert C.D | ▼ Sale | 34,398 | $18.49 | $636K | -8.6% | 4 tranches |
| Oct 28, 2025 | Novo Holdings A/S10% | ▲ Buy | 952,941 | $17 | $16.2M | +34.9% | — |
| Oct 28, 2025 | Catalyst4, Inc.10% | ▲ Buy | 5,441,176 | $17 | $92.5M | +38.2% | indirect |
Every $MPLT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? MapLight Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MPLT feed.